Sathyanarayanan Sriram 4
4 · Codiak BioSciences, Inc. · Filed Feb 21, 2023
Insider Transaction Report
Form 4
Sathyanarayanan Sriram
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-08-16+7,350→ 9,102 total - Sale
Common Stock
2022-08-17$2.21/sh−2,283$5,051→ 6,819 total - Exercise/Conversion
Common Stock
2023-02-16+7,350→ 14,169 total - Sale
Common Stock
2023-02-17$0.59/sh−2,407$1,425→ 11,762 total - Exercise/Conversion
Restricted Stock Units
2022-08-16−7,350→ 22,050 total→ Common Stock (7,350 underlying) - Exercise/Conversion
Restricted Stock Units
2023-02-16−7,350→ 14,700 total→ Common Stock (7,350 underlying)
Footnotes (4)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
- [F3]Each RSU represents a contingent right to receive one share of common stock.
- [F4]On February 16, 2022, the reporting person was granted 29,400 RSUs, vesting in four equal installments every six months beginning on the six months anniversary of the grant date.